Main reason for that includes at least two difficulties, one is the uncertainty of malignant cells’ development trend after antiangiogenic therapy, which comprises ‘dormant status’22 due to starvation in blood supply and activated stem‐like cell transformation induced by antiangiogenic hypoxia.23 For above reason, it’s hard to predict antiangiogenic efficacy aheading treatment through the expression extent of angiogenesis‐related factors on endothelial cells of micrangium around cancer, like what we did on EGFR mutation on cancer cells for predicting EGFR‐TKIs’ efficacy. The gene discussed is EGFR; the disease is cancer.